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Abstract
Background: Bronchial challenge tests are used to evaluate bronchial responsiveness in diagnosis
and follow-up of asthmatic patients. Challenge induced cough has increasingly been recognized as
a valuable diagnostic tool. Various stimuli and protocols have been employed. The aim of this study
was to compare cough and dyspnea intensity induced by different stimuli.
Methods: Twenty asthmatic patients underwent challenge tests with methacholine, bradykinin and
exercise. Cough was counted during challenge tests. Dyspnea was assessed by modified Borg scale
and visual analogue scale. Statistical comparisons were performed by linear mixed-effects model.
Results: For cough evaluation, bradykinin was the most potent trigger (p < 0.01). In terms of
dyspnea measured by Borg scale, there were no differences among stimuli (p > 0.05). By visual
analogue scale, bradykinin induced more dyspnea than other stimuli (p ≤ 0.04).
Conclusion: Bradykinin seems to be the most suitable stimulus for bronchial challenge tests
intended for measuring cough in association with bronchoconstriction.
Background
Cough is one of the most common symptoms in asthma
patients, although little attention has been paid to its role
in asthma diagnosis and follow-up. Some recent studies
from Europe have suggested that cough provoked by inha-
lation challenges may be useful in diagnosing asthma
[1,2], and also in evaluating the response to asthma treat-
ment [3]. These studies support the concept that cough
could be utilized as a surrogate for bronchoconstriction
when studying patients likely to be unable to perform
spirometry. However, the relationship between intensity
of coughing and level of bronchoconstriction is still a
matter of debate.
Sheppard et al studied the relationship between cough
and bronchoconstriction caused by inhaled distilled
water aerosol in subjects with asthma. Atropine caused
inhibition of the water-induced bronchoconstriction, but
did not inhibit cough. Their data suggest that water-
induced bronchoconstriction involves cholinergic nerves
and that water-induced cough is not dependent on bron-
choconstriction[4]. On the other hand, Koskela et al
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showed that direct, indirect, and combined airway chal-
lenges are able to provoke cough, but the significance of
the cough response differs considerably among the chal-
lenge stimuli[2].
Therefore, the utility of cough during bronchial challenges
in diagnosing asthma may depend on the stimulus. In the
present study, we hypothesized that bradykinin causes
more cough and dyspnea. Bradykinin is thought to be an
indirect stimulus, i.e., causes airflow limitation by an
action on cells other than the effector cells (smooth mus-
cle). Possible mechanisms by which bradykinin may
cause bronchoconstriction involve the stimulation of sen-
sory nerves to induce smooth muscle contraction via neu-
ral reflex pathways and this may contribute to cough
stimulus in asthma [5]. The aim of this study was to com-
pare cough and dyspnea intensity induced by bradykinin,
methacholine, and exercise challenge.
Methods
Subjects
Asthma was defined by clinician diagnosis [6]. We
recruited asthmatics with history of symptoms induced by
exercise that were studied during a clinically stable period,
without symptoms of upper respiratory tract infection for
at least six weeks prior to the study. Exclusion criteria
were: smoking, other pulmonary disease, pregnancy, use
of medication other than bronchodilator or inhaled ster-
oids, inability to perform the exercise challenge, incapac-
ity to understand the protocol, including illiteracy. Long-
acting β2-agonist was withheld for at least 24 hours, and
short-acting β2-agonist was withheld for 12 hours before
evaluations. Moreover, the time interval between the last
dose of bronchodilator and the challenge test was estab-
lished to be the same before all tests. All subjects gave
informed consent to this Institutional Review Board
approved protocol.
Study design
Three challenge tests were performed on three different
days, at the same time of day, at least 48 hours apart. Tests
sequence was randomly determined. Subjects had their
coughs counted during every challenge test and were
requested to rate discomfort associated with the act of
breathing one minute before every FEV1 maneuver during
all challenge tests. Patients registered dyspnea intensity in
a VAS and answered, according to modified Borg scale.
Assessment of cough
A cough is a reflex act with an explosive expiration. The
three phases of a cough are: 1) a deep inspiration; 2) com-
pression of air in the lungs and airways by forceful con-
centration of the expiratory muscles coupled with closure
of the glottis and opening of the larynx; 3) sudden explo-
sive expiration followed by narrowing of the glottis and
return of the larynx to its normal inspiratory position [7].
We counted every phase 3 as one cough. This counting
was performed during two minutes before spirometry
(baseline evaluation) and during two minutes before
every FEV1 maneuver during inhalation challenge tests.
During exercise challenge test, cough was counted before
and after exercise (during all recovering time). The act of
clearing the throat was not considered as a cough. The
same technician counted cough all over the study, in a
quiet and calm environment, without performing other
tasks.
Assessment of perception of dyspnea
Subject was free to interpret respiratory discomfort in any
way he or she felt appropriate, and no further instructions
were given. The subject rated the intensity of symptom on
the modified Borg scale, a scale numbered 0 to 10. These
are tagged to descriptive phrases, describing increasing
intensities of asthma sensations, and subjects were not
restricted to whole numbers[8]. Visual analogue scale was
an horizontal straight line (10 cm) labeled "no breathless-
ness at all" (0 cm) at one end and "the most extreme
breathlessness ever experienced" (10 cm) at the other,
whereby equal distances are meant to represent equal
severities of breathlessness [9,10]. During tests, subjects
were blinded to their lung function response and to previ-
ous dyspnea scores.
Inhalation challenge tests
Methacholine and bradykinin challenge tests were per-
formed following the same protocol, according to a stand-
ardized tidal breathing method. For safety reasons,
baseline FEV1 ≥ 50% of predicted value was requisite to
start challenge tests. Acetyl-β-methylcholine chloride
(Sigma-Aldrich, Saint Louis, MO, USA) and tri-acetate of
bradykinin in normal phosphate-buffered saline solution
were aerosolized by a DeVilbiss 646 nebulizer (Sunrise
Medical HHG Inc, Somerset, PA, USA) during tidal
breathing for two minutes, driven by a computer-acti-
vated dosimeter (Koko Digidoser System, PDS Instrumen-
tation, Inc., Louisville, CO, USA). Phosphate-buffered
saline solution was inhaled first, followed by test solution
in two-fold increasing concentrations (0.06 to 16 mg/ml).
Measurements of FEV1 were made using the Koko Spirom-
eter before test and two minutes after every inhalation.
Cough was counted during these two-minute intervals.
The challenge test was discontinued if FEV1 dropped 20%
or more from baseline. The provocative concentration of
methacholine or bradykinin resulting in a 20% fall in
FEV1 (PC20 MCh or PC20 BK, respectively) was calculated
by linear interpolation of dose-response curves [11].
Exercise challenge test
After one minute of light exercise on the inclined (10°)
treadmill, the speed was quickly increased to achieve 80%Cough 2009, 5:6 http://www.coughjournal.com/content/5/1/6
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of the maximum predicted heart rate; this speed was then
maintained for six minutes. Standard measurements of
spirometry were obtained before, immediately after and
5, 10, 15, 20, 30 and 45 minutes after exercise. Cough was
counted before and after exercise (during all the recover-
ing time). The maximum percentage of change from base-
line was calculated as 100 × the decrease in FEV1/baseline
FEV1 [12]. With the aid of air conditioning apparatus, the
exercise laboratory temperature and relative humidity
were kept at 20° to 22°C and 50% to 55%, respectively.
Statistical analysis
Since the response variables are assumed to be continu-
ous, linear mixed-effects models were used to allow for
dependencies between measurements on the same
patient. These models were used to verify the effect of
challenge tests on dyspnea (Borg and VAS) and on cough
[13], considering that each patient underwent all the three
different tests. We assume that these models have nor-
mally distributed residual with mean zero and constant
variance. Like this, the distribution of residuals was graph-
ically verified and when it was not compatible with this
presupposition, new models were adjusted with loga-
rithms transformation. Statistical interaction was exam-
ined by including the independent variables and their
cross-product term in the model. Age, gender, atopy sta-
tus, body mass index, FEV1, baseline FEV1, all stimuli
(bradykinin, methacholine and exercise), baseline symp-
tom, inhaled corticosteroid dose, tests sequence and inter-
cept were considered as covariables. All the models are
fitted by the method of maximum likelihood using the
SAS software 9th version [14].
Results
We studied 20 asthmatic outpatients (10 women; age
range: 21 – 46 years). All subjects were on inhaled short-
acting β2-agonists as rescue medication and 14 subjects on
inhaled corticosteroid therapy. Characteristics of studied
subjects can be seen in Table 1. The geometric mean PC20
MCh was 0.36 (range 0.08 to 2.35 mg/ml), and the geo-
metric mean PC20 BK was 0.68 (range 0.05 to 3.87 mg/
ml). The mean (± SD) FEV1 fall after exercise was 20.45%
± 3.43%.
Table 2 shows intensity of symptoms among stimuli.
Cough induced by bradykinin was more intense. Bradyki-
nin also led to more intense breathlessness detected by
VAS scale, but not by Borg scale. The pairwise compari-
sons of challenge tests are shown in Table 3. For the cough
evaluation, bradykinin caused more cough in comparison
Table 1: Characteristics of the subjects studied
Subject Gender Age
(years)
BMI FEV1
(L)
FEV1
(%)
Tests sequence PC20 MCh (mg/ml) PC20 BK (mg/ml)
1 M 23 23.8 3.24 76 BK, EIB, MCh 0.83 2.30
2 M 23 24.2 3.56 83 EIB, BK, MCh 0.21 0.15
3 M 21 24.0 2.98 69 BK, EIB, MCh 0.19 1.16
4 F 30 19.1 3.44 110 MCh, EIB, BK 1.13 3.87
5 F 43 24.8 2.55 83 EIB, MCh, BK 0.56 0.42
6 F 23 25.8 2.26 68 MCh, BK, EIB 0.13 0.58
7 F 45 25.7 2.13 80 EIB, BK, MCh 0.47 1.62
8 F 39 27.9 1.66 54 MCh, BK, EIB 0.14 0.12
9 F 24 33.6 2.81 87 BK, MCh, EIB 0.16 1.17
10 F 38 31.2 2.56 88 BK, MCh, EIB 1.00 0.22
11 M 39 22.1 2.90 74 EIB, MCh, BK 0.62 0.06
12 F 24 32.7 3.16 91 MCh, EIB, BK 0.17 1.16
13 M 24 19.2 3.73 90 EIB, MCh, BK 0.42 1.48
14 M 27 31.8 3.26 77 MCh, BK, EIB 0.28 2.37
15 M 46 26.8 3.29 83 EIB, BK, MCh 0.38 0.71
16 M 33 23.1 3.21 73 BK, MCh, EIB 2.35 2.32
17 F 24 19.6 2.57 80 MCh, EIB, BK 0.95 3.56
18 F 26 21.8 2.30 80 MCh, EIB, BK 0.15 0.20
19 M 38 24.6 2.25 64 BK, MCh, EIB 0.08 0.05
20 M 32 28.7 3.00 80 MCh, BK, EIB 0.58 1.73
Mean 31 25.5 2.84 79.5 0.36a 0.68a
SD 8 4.4 0.54 11.6 2.45b 3.84b
M: male; F: female; BMI: body mass index; FEV1: Forced expiratory volume in one second; MCh: methacoline; BK: bradykinin; EIB: exercise-induced 
bronchospasm; PC20: provocative concentration that results in a 20% fall in FEV1.
a geometric mean. b geometric standard deviation.Cough 2009, 5:6 http://www.coughjournal.com/content/5/1/6
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with methacholine and exercise (p < 0.01). There were no
differences between exercise and methacholine (p = 0.31).
In terms of dyspnea measured by Borg scale, there were no
differences among stimuli (p ≥ 0.15). When dyspnea was
measured by VAS, bradykinin induced more dyspnea than
exercise (p = 0.04) and than methacholine (p = 0.02).
The baseline FEV1 had effect on cough (estimate 3.10;
95%CI 0.77–5.43; p < 0.01) and on dyspnea evaluated by
Borg scale (estimate 6.96; 95%CI 2.95–10.96; p < 0.01) or
by VAS (estimate 5.08; 95%CI 0.89–9.26; p = 0.02). These
positive-estimate values indicate that higher baseline FEV1
leads to more symptoms during FEV1 fall. For the follow-
ing covariables, no effect has been detected on cough or
dyspnea: body mass index, atopy status, age, gender, tests
sequence and inhaled corticosteroid dose.
Discussion
In this cross over study, 20 asthmatic subjects were evalu-
ated. Self-reported ratings of the intensity of dyspnea
(assessed by Borg and VAS) and coughing counts were
made during bradykinin, methacholine and exercise
induced bronchoconstriction. The study showed that
bradykinin induced more cough and dyspnea than meth-
acholine and exercise. As expected, dyspnea increased dur-
ing challenge tests, so did cough. Some studies failed to
show this dose-related increase in cough counts during
bronchoconstriction [15,16].
Our data support the proposal of using cough to evaluate
bronchial responsiveness in special groups of patients.
Technical difficulties in performing spirometry are com-
mon: one out of five elderly subjects cannot perform
spirometry according to the international guidelines [17].
Similarly, approximately 30% of pre-school children are
Table 2: Symptoms intensity during bronchoconstriction
Stimuli Cough (total of episodes) Dyspnea – Borg Dyspnea – VAS
Bradykinin 72.40 ± 69.26* 3.60 ± 2.30 3.26 ± 2.47#
Methacholine 18.15 ± 20.58 3.40 ± 2.40 2.94 ± 2.32
Exercise 5.95 ± 8.22 2.10 ± 2.00 2.12 ± 2.05
Mean ± Standard Deviation.
* # Significant differences (p < 0.05) in comparison with other stimuli according to linear mixed-effects model.
Table 3: Pairwise comparisons according to linear mixed-effects model of modified Borg scale, visual analogue scale (VAS) and cough 
(logarithmic scale).
Cough
Comparisons Mean Difference* 95% CI p-value
Bradykinin × Exercise 2.79 (1.83; 3.76) < 0.01
Bradykinin × Methacholine 2.22 (1.12; 3.32) < 0.01
Exercise × Methacholine -0.58 (-1.69; 0.53) 0.31
Dyspnea – Borg
Comparisons Mean Difference* 95% CI p-value
Bradykinin × Exercise 1.20 (-0.41; 2.81) 0.15
Bradykinin × Methacholine 0.59 (-1.23; 2.43) 0.52
Exercise × Methacholine -0.60 (-2.46; 1.25) 0.52
Dyspnea – VAS
Comparisons Mean Difference* 95% CI p-value
Bradykinin × Exercise 1.76 (0.09; 3.42) 0.04
Bradykinin × Methacholine 2.28 (0.39; 4.18) 0.02
Exercise × Methacholine 0.53 (-1.39; 2.44) 0.59
CI: confidence interval. *The model was adjusted by intercept, age, gender, atopy status, body mass index, FEV1, baseline FEV1, bradykinin, 
methacholine and exercise, baseline symptom, inhaled corticosteroid dose and tests sequence.Cough 2009, 5:6 http://www.coughjournal.com/content/5/1/6
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unable to perform acceptable efforts [18]. In the evalua-
tion of challenge induced cough, bradykinin would prob-
ably be the best stimulus because it could increase the
sensitivity of the test by increasing cough intensity.
In addition, during challenge tests, cough and dyspnea
were significantly more intense in subjects with higher
baseline pulmonary function (baseline FEV1). Probably,
patients with prolonged airflow obstruction would be less
breathless for any given reduction in FEV1 than those with
higher baseline FEV1, a process known as temporal adap-
tation [19]. This is in favor of the use of cough to define
positive bronchial challenge test, given that most patients
who need challenge tests are not severe enough to have
very low FEV1.
Some theories are able to explain why, in patients with
asthma, the severity of breathlessness is greater during
bradykinin than methacholine or exercise challenge at
given levels of airway obstruction: a) bradykinin chal-
lenge test causes more cough and this could interfere in
dyspnea perception, increasing it; b) methacholine has
PC20 lower than bradykinin and this could be associated
with faster bronchospasm, shorter sensory duration of the
experience; c) intensity of asthma symptoms depends on
the mechanisms that are involved in the induction of air-
way obstruction [10]. The difference in mode of action
among three stimuli should be considered potential deter-
minant of breathlessness severity. For instance, after exer-
cise, various sensations from physical discomfort could
have influenced scoring of perceived breathlessness and it
is not known what the effect of exercise itself is on cough
or sensation of dyspnea. One solution to these potential
problems could be a bronchial provocation challenge that
would reproduce the hyperventilation of exercise, e.g.
eucapnic voluntary hyperventilation of cold and dry air
[20].
Another study has showed that bradykinin inhalation
caused cough and retroesternal discomfort, but authors
did not evaluate cough quantitatively [16]. In a more
recent study with 12 subjects with mild asthma, authors
recorded and counted coughs episodes. They showed that,
in general, bradykinin induced more coughing than did
methacholine, however, there were some subjects who
rarely coughed to either stimuli, whereas others had a
marked cough response regardless of the stimuli [15].
Despite cough is a very common symptom and the mech-
anisms contributing to it are widely studied, there has
been much debate, for instance, surrounding the identity
of the airway afferent nerve subtype that precipitates reflex
coughing. Studies in experimental animals and in
humans show clearly that multiple afferent nerve sub-
types (mechanosensors and chemosensors) might be
involved in the production of reflex coughing. However,
not all stimuli evoke cough under all conditions. This
might suggest divergence between multiple reflex path-
ways or the existence of primary and secondary cough
afferent pathways [21]. Also, there is a suspicious that a
complex allergic reaction in the airway may be involved in
the development of antigen-induced increase in cough
reflex sensitivity [22]. There is evidence of the involve-
ment of airway vagal afferents, such as sensory C-fibers,
and rapidly adapting receptors in the cough reflex, as well
as in other symptoms of respiratory disease, such as bron-
chospasm [23,24]. Bradykinin, capsaicin and citric acid,
stimuli that are known to active airway chemosensors, are
amongst the most potent tussigenic agent in conscious
animals and humans[21].
The mechanisms of tussive and bronchoconstrictor
responses to bradykinin may be the same, via C-fibers
[25]. The non-myelinated C-fibers contain the tachyki-
nins substance P, neurokinin A and neurokinin B which,
upon release, act on NK1, NK2, NK3 receptors respectively
to mediate several functions [26]. Whilst inhalation of cit-
ric acid stimulates both C-fibers and rapidly adapting
receptors, capsaicin appears to stimulate only C-fibers and
both these agents have been shown to induce cough, in
several species including man, and also bronchoconstric-
tion [21,26-30].
In several studies, dyspnea score are usually plotted
against percentage of fall in FEV1 and individual symp-
toms/FEV1 ratios are used to represent an index of dysp-
nea, and their corresponding intercepts, representing
baseline symptoms. These variables are calculated by lin-
ear regression analysis [19,31]. The mixed procedure fits a
variety of mixed linear models to data and enables the use
of these fitted models to make statistical inferences about
the data. The linear mixed-effects models, therefore, pro-
vides flexibility of modeling not only the means of data
(as in the standard linear model) but their variances and
covariances as well [14].
Some studies make video recordings or employ simulta-
neous recordings of flow rate, air volume, subglottic pres-
sure and acoustic signal to evaluate cough. However, the
use of different devices could interfere with dyspnea sen-
sation, plus, there is a recent study (comparing video
recordings and audio recordings) showing that trained
observers are able to achieve good agreement counting
cough manually from audio recordings [32]. Another
study showed that the agreement between simultaneous
(at the same time when the test is being conducted) and
video counting of coughs is generally good. To ensure reli-
able simultaneous cough counting, challenge tests should
be performed in a quiet environment, applying as littleCough 2009, 5:6 http://www.coughjournal.com/content/5/1/6
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unnecessary equipment and measurements as possible
[33].
Conclusion
Bradykinin challenge provides the strongest coughing
intensity and breathlessness for a given fall in FEV1, and is
thereby recommended for protocols planned to evaluate
cough. Bradykinin may act on neural mechanisms that
modulate symptoms, increasing cough and dyspnea in
asthmatic patients. These data corroborate previous stud-
ies that showed, in experimental models, a role for brady-
kinin in the mechanism of cough.
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